Neurocrine Biosciences Highlights Innovations at Stifel CNS Forum 2026 on Neurological Treatments

Neurocrine Biosciences Takes Center Stage at Stifel CNS Forum

Neurocrine Biosciences, Inc., a leading biopharmaceutical company, announces its participation in the upcoming Stifel 2026 Virtual CNS Forum set for March 17, 2026, at 4:30 PM EST. This event marks a significant moment for the company, spotlighting its commitment to addressing critical neurological and psychiatric disorders. Investors and interested stakeholders can tune into the live webcast available on the company's website, with a replay provided shortly after the event for those unable to attend in real time. Neurocrine aims to showcase its advancements and insights into developing impactful treatments in this sector.

Recognized for its diverse portfolio of FDA-approved therapies, Neurocrine focuses on treating challenging conditions such as tardive dyskinesia, Huntington's disease, and classic congenital adrenal hyperplasia. The company also collaborates with AbbVie in developing innovative treatments for endometriosis and uterine fibroids. With a track record spanning three decades, Neurocrine’s dedication to discovering and commercializing therapies that meet unmet medical needs positions it as a leader in the biopharmaceutical industry. The firm’s tagline, "You deserve brave science," embodies its mission to leverage scientific breakthroughs to enhance patient care and improve quality of life for those facing complex medical conditions.

As Neurocrine advances its pipeline with multiple compounds currently in mid- to late-phase clinical development, the company underscores its strategic focus on neuroscience. By utilizing insights from ongoing scientific research, Neurocrine aims to develop therapeutic solutions that tackle the burdens of debilitating diseases. Their participation in the Stifel CNS Forum is not just an opportunity to engage with investors but also a platform to communicate developments that are reflective of their broader commitment to innovation and patient-focused solutions.

In addition to the upcoming forum, stakeholders are encouraged to stay connected with Neurocrine through their website and various social media platforms, including LinkedIn, X, Facebook, and YouTube. The company's proactive approach to engagement signifies its openness to collaboration and transparency in its mission to foster advancements in the treatment of neurological, psychiatric, endocrine, and immunological disorders. As Neurocrine continues to expand its therapeutic offerings, the industry watches closely.